| Literature DB >> 28220079 |
Hiroki Ito1, Anthony E Pickering1, Yasuhiko Igawa2, Anthony J Kanai3, Christopher H Fry1, Marcus J Drake1.
Abstract
Background: Mouse urodynamic tests are fundamental to understanding normal lower urinary tract (LUT) function. These experiments also contribute to our understanding of neurological dysfunction, pathophysiological processes, and potential mechanisms of therapy.Entities:
Keywords: cystometry; electromyography of the external urethral sphincter; frequency-volume chart; lower urinary tract dysfunction; mouse model
Year: 2017 PMID: 28220079 PMCID: PMC5292568 DOI: 10.3389/fphys.2017.00049
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1A 24-h trace of a frequency-volume charts (FVC) (upper) and water intake (lower) of a male mouse at the age of 10 weeks. Each animal was separately placed in a conscious condition, without any restraint, in a metabolic cage that allows precise measurement of voiding episodes, voided volume, drinking episodes, and amounts (001–006 metMCM/TOA-UFabolic cage, Mitsubishi Chemical Medience, Tokyo, Japan). After 24-h adaptation, voided volume, voiding frequency, and water intake volume were recorded using a PowerLab® data acquisition system continuously for 24 h starting at 9:00 pm. The mice had free access to water and food during recording.
Summary of clinical neuro-urodynamic tests for human and relevant mouse neuro-urodynamic tests.
| Non-invasive | Symptom score | Various questionnaires | Not applicable |
| such as | |||
| International Prostate Symptom Score (IPSS) | |||
| QOL question | |||
| Bladder diary | Micturition chart | Metabolic cage | |
| Frequency volume chart (FVC) | Frequency volume chart (FVC) | ||
| Bladder diary | Voiding Spot Assay (VSA) | ||
| Urodynamic tests | Urinary flow rate | Not applicable | |
| Post-void urine (PVR) analysis | |||
| Other tests | Near intra-red spectroscopy (NIRS) | Phenotyping (Distended bladder, Perineal for staining) | |
| Invasive | Urodynamic tests | Filling cystometry (storage phase) | Filling cystometry (storage phase) |
| Pressure-flow study (voiding phase) | Pressure-flow study (voiding phase) | ||
| Electrophysiology | |||
| Future | Special tests | Functional magnetic resonance imaging (fMRI) | Functional magnetic resonance imaging (fMRI) |
| Positron emission tomography (PET) | Positron emission tomography (PET) | ||
| Electrophysiology | |||
Figure 2Cystometry and EMG recordings from spinal cord intact (A) and T8–T9 spinal cord injury (SCI; B) mice 2 weeks post-injury with the brain rostral to the supracollicular level sectioned from the brainstem and removed. Transperineal recording of the external urethral sphincter is combined with conventional filling cystometry. (A-1): This shows the guarding reflex that prevents leaking as bladder pressure approaches threshold. This is followed by increased phasic (bursting) and decreased tonic activity during which voiding occurs and pressure returns to baseline. (B): Following transection and the development of detrusor-sphincter-dyssynergia (DSD; B-1), when the bladder contracts, tonic sphincter activity increases resulting in non-voiding contractions and eventually overflow incontinence.
Summary of invasive tests for mouse urodynamic studies.
| Conscious | 10 | C57BL/6J | m | 25 | 40.8 ± 2.0 | 146 ± 42 | 7.5 ± 2.8 | 18.6 ± 4.3 | 30.3 ± 4.0 | cmH2O | Aizawa et al., |
| 10 | C57BL/6 | m | NA | 20–30 | 140 ± 23.0 | NA | 17.9 ± 3.0 | 19.8 ± 1.8 | mmHg | Cornelissen et al., | |
| 10 | f | NA | 20–30 | 143 ± 28.0 | NA | 12.2 ± 2.5 | 19.3 ± 2.4 | ||||
| 10 | Balb/CAN | m | NA | 20–30 | 30.3 ± 4.0 | NA | 25.5 ± 5.2 | 19.2 ± 2.8 | |||
| 10 | f | NA | 20–30 | 40.5 ± 7.3 | NA | 18.1 ± 3.2 | 19.0 ± 2.5 | ||||
| 10 | A/J | m | NA | 20–30 | 50.0 ± 4.3 | NA | 5.3 ± 6.3 | 17.2 ± 2.6 | |||
| 10 | f | NA | 20–30 | 51.7 ± 8.4 | NA | 16.1 ± 3.5 | 18.4 ± 4.3 | ||||
| 10 | B6:129 | m | NA | 20–30 | 164 ± 49.0 | NA | 16.9 ± 1.8 | 21.5 ± 3.0 | |||
| 10 | f | NA | 20–30 | 184 ± 59.0 | NA | 13.9 ± 2.5 | 19.7 ± 2.7 | ||||
| 10 | 129 | m | NA | 20–30 | 50.2 ± 11.9 | NA | 14.4 ± 1.8 | 15.8 ± 2.3 | |||
| 10 | f | NA | 20–30 | 77.5 ± 12.9 | NA | 10.8 ± 1.4 | 16.1 ± 1.8 | ||||
| 41.7 | WT (129/SvJ) | m | 18–23 | NA | 240 ± 20 | 7.1 ± 0.9 | 17.8 ± 1.4 | 32.3 ± 2.5 | cmH2O | Igawa et al., | |
| 41.7 | f | 18–23 | NA | 170 ± 10 | 7.6 ± 0.7 | 18.8 ± 0.9 | 33.4 ± 2.4 | ||||
| 10 | C57BL/6 | m | 6 | 20–30 | about 180 | about 8 | NA | NA | mmHg | Mingin et al., | |
| 25 | Balb/CJ | f | NA | 20.2 ± 0.4 | 110 ± 20 | 7.11 ± 1.0 | 12.12 ± 1.22 | 63.71 ± 5.21 | cmH2O | Pandita et al., | |
| 25 | WT (DBA/1LacJ) | NA | NA | 17.2 ± 0.4 | 49.5 ± 7.6 | 6.3 ± 2.1 | 12.5 ± 2.2 | 36.0 ± 4.5 | cmH2O | Schröder et al., | |
| 25 | MNRI | f | NA | 25.7 ± 0.4 | 150 ± 20 | 5.9 ± 1.3 | 9.5 ± 1.0 | 40.3 ± 3.3 | cmH2O | Schröder et al., | |
| 25 | C57BL/6J | f | NA | 15–37 | not obtained | NA | about 20 | about 40 | cmH2O | Smith and Kuchel, | |
| 33.3 | WT (albino FVB) | m | 4–6 mo | NA | 200 ± 40 | 29.9 ± 7.0 | 42.2 ± 2.5 | 59.0 ± 5.4 | cmH2O | Soler et al., | |
| 33.3 | f | 18 mo | NA | 170 ± 60 | 29.9 ± 2.0 | 47.3 ± 2.1 | 64.5 ± 15.7 | ||||
| 15 | WT (129Sv and C57BL/6J) | f | 12 | 24.3 ± 0.9 | 130 ± 10 | NA | NA | 34.9 ± 1.6 | mmHg | Chen et al., | |
| Restrained | 10 | C57BL/6N | f | 9 | 18–20 | 50 ± 20 | 8.1 ± 1.3 | NA | 32.0 ± 5.0 | cmH2O | Kadekawa et al., |
| 25 | C57BL/6 | f | 8–10 | NA | about 20 | NA | NA | NA | mmHg | DePaul et al., | |
| Anesthesia | 20 | Balb/CAN | m | NA | 18–22 | 58 ± 13 | NA | NA | 12 ± 5 | mmHg | Beamon et al., |
| 13.3 | 129S1/SvImJ | m | 10–12 | 27.1 ± 0.8 | 123.6 | NA | NA | 39 ± 1.4 | mmHg | Bjorling et al., | |
| 13.3 | f | 10–12 | 21.8 ± 0.8 | 196.8 ± 28 | NA | NA | 51.5 ± 2.4 | ||||
| 13.3 | C57BL/6J | m | 10–12 | 27.6 ± 0.5 | 42.0 | NA | NA | 21.9 ± 1.5 | |||
| 13.3 | f | 10–12 | 19.2 ± 0.2 | 32 ± 2.7 | NA | NA | 27.1 ± 1.2 | ||||
| 13.3 | NOD/ShiLtJ | m | 10–12 | 29.1 ± 1.3 | 90.0 | NA | NA | 25 ± 1.8 | |||
| 13.3 | f | 10–12 | 24.5 ± 0.4 | 148 ± 18.7 | NA | NA | 31.5 ± 2.3 | ||||
| 13.3 | CAST/EiJ | m | 10–12 | 16.6 ± 0.3 | 111.1 | NA | NA | 25.4 ± 3.1 | |||
| 13.3 | f | 10–12 | 13.4 ± 0.6 | 77.3 ± 10.7 | NA | NA | 22.8 ± 1.2 | ||||
| 20 | C57BL/6 | m | 10–12 | NA | 48 | 6.9 ± 0.5 | 4.2 ± 0.2 | 26.6 ± 1.0 | cmH2O | Boudes et al., | |
| 25 | Balb/CAN | f | NA | 26.8 | 57.5 | NA | NA | 26.8 ± 2.4 | mmHg | Comiter and Phull, | |
| 100 | WT (ICR and C57 strains) | f | 4–6 mo | 32.3 | 260 ± 110 | NA | NA | NA | mmHg | Lemack et al., | |
| 25 | C57BL/6 | f | 2 mo | about 18 | about 50 | about 12 | about 40 | 48 ± 2.5 | cm/W | Smith et al., | |
| 25 | 12 mo | about 26 | about 100 | about 8 | about 30 | 47 ± 1.2 | |||||
| 25 | 22 mo | about 26 | about 120 | about 6 | about 30 | 44 ± 1.7 | |||||
| 25 | 26 mo | about 30 | about 200 | about 4 | about 25 | 44 ± 2.3 | |||||
| 20 | C57BL/6J | f | 11–13 | NA | about 80 | about 3 | NA | about 40 | cmH2O | Franken et al., | |
| 80 | WT (FVB/N) | m | 4–9 mo | 24.3–37.7 | NA | NA | NA | 25.6 ± 4.8 | mmHg | Streng et al., | |
| 80 | WT (FVB/N) | m | 7–8 mo | 30.6 ± 3.3 | NA | NA | NA | 28.5 ± 5.6 | mmHg | Streng et al., | |
| 10 | WT (C57BL6) | m | 9–17 | 25.7 ± 1.1 | about 200 | NA | NA | NA | cmH2O | Birder et al., | |
| 100 | WT (129Sv and C57BL/6) | f | NA | 18.7 | 420 ± 210 | NA | NA | 59.5 ± 12.8 | cmH2O | Sutherland et al., | |
| 25 | C57BL/6J | f | NA | 15–37 | 90 ± 20 | NA | about 40 | about 60 | cmH2O | Smith and Kuchel, | |
| Decerebrated | 10 | WT (C57BL/6Cr) | m | 8–12 | 22.1 ± 0.3 | 131 ± 11 | NA | 3.8 ± 0.4 | 23.0 ± 2.2 | mmHg | Yoshiyama et al., |
f, female; m, male; NA, not assessed; mo, months; WT, wild type.
Summary of non-invasive tests for mouse urodynamic studies.
| Metabolic cage | C57BL/6J | m | 5 | 16.5 ± 0.3 | 104.3 ± 7.6 | 24 h | Aizawa et al., |
| 9 | 22.0 ± 0.3 | 137.1 ± 5.4 | |||||
| 13 | 24.3 ± 0.3 | 177.8 ± 8.6 | |||||
| 17 | 25.6 ± 0.2 | 251.8 ± 15.4 | |||||
| 21 | 26.9 ± 0.3 | 267.4 ± 22.5 | |||||
| WT (C57BL/6Cr) | m | 8–12 | 22.1 ± 0.3 | about 380 | 24 h | Yoshiyama et al., | |
| WT (129Sv and C57BL/6) | f | NA | 15–23 | 490 ± 130 | 14 h (overnight) | Sutherland et al., | |
| WT (129Sv and C57BL/6J) | f | 12 | 24.3 ± 0.9 | 160 ± 30 | 48 h | Chen et al., | |
| Voiding spot assay | 129S1/SvImJ | m | 10–12 | 27.1 ± 0.8 | 40.1 | 4 h (9 a.m.–2 p.m.) | Bjorling et al., |
| f | 10–12 | 21.8 ± 0.8 | 103.7 | ||||
| C57BL/6J | m | 10–12 | 27.6 ± 0.5 | 86.7 | |||
| f | 10–12 | 19.2 ± 0.2 | 68.8 | ||||
| NOD/ShiLtJ | m | 10–12 | 29.1 ± 1.3 | 40 | |||
| f | 10–12 | 24.5 ± 0.4 | 51.9 | ||||
| CAST/EiJ | m | 10–12 | 16.6 ± 0.3 | 3.8 | |||
| f | 10–12 | 13.4 ± 0.6 | 15.9 | ||||
| WT (C57BL6) | m | 9–17 | 25.7 ± 1.1 | NA | 1 h | Birder et al., | |
| C57BL/6 | m | NA | 20–30 | NA | 1 h (8–11 a.m.) | Cornelissen et al., | |
| f | NA | 20–30 | NA | ||||
| Balb/CAN | m | NA | 20–30 | NA | |||
| f | NA | 20–30 | NA | ||||
| A/J | m | NA | 20–30 | NA | |||
| f | NA | 20–30 | NA | ||||
| B6:129 | m | NA | 20–30 | NA | |||
| f | NA | 20–30 | NA | ||||
| 129 | m | NA | 20–30 | NA | |||
| f | NA | 20–30 | NA | ||||
| WT (C57BL/6 and DBA/2) | f | 7–8 | 27.6 ± 2.25 | 430 ± 80 | overnight 8 h | Jusuf et al., | |
| C57BL/6 | m | 10–12 | unknown | 108.3 ± 14.1 | 3 h (unknown) | Boudes et al., |
f, female; m, male; NA, not assessed; WT, wild type.